Clinical Trials

Multiple clinical trials sponsored by EMD Serono Research & Development Institute and Merck Healthcare KGaA evaluate enpatoran across Phase 1, Phase 2, and Phase 3 studies. These investigations target systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, and polymyositis, alongside pharmacokinetic evaluations in healthy volunteers and individuals with renal impairment. Recruitment statuses range from completed early-phase studies to actively recruiting trials assessing long-term efficacy and safety, though a clinical trial evaluating dermatomyositis was terminated.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07355218 RECRUITING
Systematic Lupus Erythematosus; Cutaneous Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.
 2026-04-01 PHASE3
NCT07332481 RECRUITING
Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.
 2026-03-10 PHASE3
NCT05540327 ACTIVE_NOT_RECRUITING
Systemic Lupus Erythematosus
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
 2022-09-16 PHASE2
NCT06589713 COMPLETED
Renal Impairment
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
 2024-09-24 PHASE1
NCT05650567 TERMINATED
Dermatomyositis; Polymyositis
EMD Serono Research & Development Institute, Inc.
 2023-01-19 PHASE2
NCT06589726 COMPLETED
Healthy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
 2024-09-10 PHASE1
NCT05162586 COMPLETED
Systemic Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.
 2022-03-31 PHASE2
NCT05110027 COMPLETED
Healthy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
 2021-11-05 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-17)

Check the Enpatoran Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Enpatoran hydrochloride is a potent, orally active dual inhibitor of Toll-like receptors 7 and 8 (TLR7/8) that selectively binds these endosomal receptors to block downstream nucleic acid sensing and pro-inflammatory cytokine signaling. By suppressing TLR7/8-mediated immune activation, enpatoran inhibits pathogenic autoimmune cascades, providing therapeutic relevance for inflammatory conditions such as systemic lupus erythematosus and cutaneous lupus erythematosus.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.